The current Presidential administration is pursuing a two-fold strategy to reduce drug costs in the U.S. While it is unclear whether and how such policies will be implemented, the proposed policies are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for our products and any additional product candidates we develop, if approved. As part of this strategy, President Trump has proposed imposing significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price in a group of other countries.
All entries for: Precision BioSciences
November 3, 2025
Precision BioSciences
Neutral Outlook
Durham, NC
51-200 employees
Most recently, on August 16, 2022, the Inflation Reduction Act of 2022 (the “IRA”), was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (which began in 2025).
Disease Area: Chronic Disease, Immune Diseases, Rare Diseases
Drug Type: Biologic
August 8, 2025
Precision BioSciences
Layoffs
Durham, NC
51-200 employees
Delaware-based Precision BioSciences has terminated an undisclosed number of employees in order to extend its cash runway into the second half of 2027.
Disease Area: Chronic Disease, Hematology, Infectious Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic